A prospective multicentre study of per-oral endoscopic myotomy (POEM) for achalasia in Australia.


Journal

The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714

Informations de publication

Date de publication:
03 2021
Historique:
received: 22 12 2019
accepted: 09 10 2020
pubmed: 22 2 2021
medline: 12 3 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

To describe the clinical and procedural outcomes of per-oral endoscopic myotomy (POEM) for achalasia in Australia. Prospective observational study in three Australian tertiary referral centres, 5 May 2014 - 27 October 2019 (66 months). Patients who had undergone POEM for achalasia. Eckardt scores calculated prior to POEM and six months, one year, and two years after POEM. The primary outcome was clinical success, defined as an Eckardt score of 3 or less without a second intervention. 142 patients underwent POEM for achalasia; their mean age was 52 years (SD, 18 years), 83 were men (58%), and the median length of hospital stay two days (IQR, 1-3 days). Their mean Eckardt score before POEM was 8.0 (SD, 2.4) and 1.1 (SD, 1.6) six months after POEM; it did not change significantly between six months and two years after POEM (mean monthly increase, 0.014 points; 95% CI, -0.001 to 0.029). A total of 127 patients (89%) improved clinically after POEM. Intra-procedural capnoperitoneum was the only risk factor associated with treatment failure (adjusted hazard ratio, 2.85; 95% CI, 1.08-7.51). Previous treatments - botulinum toxin injection (25 patients, 18%), endoscopic balloon dilatation (69, 49%), and Heller myotomy (14, 10%) - did not affect POEM outcomes. Five patients (4%) experienced major adverse events, including pneumonia, oesophageal leak, empyema and melaena, that were managed during admission and without sequelae. POEM is an effective treatment for achalasia. Significant reductions in Eckardt scores achieved by six months are sustained at two years. POEM can be both a first line definitive therapy and a salvage therapy for patients not helped by other treatments.

Identifiants

pubmed: 33611796
doi: 10.5694/mja2.50941
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-178

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 AMPCo Pty Ltd.

Références

Sadowski D, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil 2010; 22: 256-261.
Samo S, Carlson DA, Gregory DL, et al. Incidence and prevalence of achalasia in Central Chicago, 2004-2014, since the widespread use of high-resolution manometry. Clin Gastroenterol Hepatol 2017; 15: 366-373.
Kahrilas P, Bredenoord A, Fox M, et al; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27: 160-174.
Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil 2005; 17: 13-21.
Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet 2014; 383: 83-93.
Eckardt VF. Clinical presentation and complications of achalasia. Gastrointest Endosc Clin N Am 2001; 11: 281-292.
Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 1992; 103: 1732-1738.
Pandolfino JE, Kahrilas PJ. Presentation, diagnosis, and management of achalasia. Clin Gastroenterol Hepatol 2013; 11: 887-897.
Boeckxstaens GE, Annese V, des Varannes SB, et al; European Achalasia Trial Investigators. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med 2011; 364: 1807-1816.
Ponds FA, Fockens P, Lei A, et al. Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom severity and treatment outcomes among treatment-naive patients with achalasia: a randomized clinical trial. JAMA 2019; 322: 134-144.
Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg 2009; 249: 45-47.
Inoue H, Sato H, Ikeda H, et al. Per-oral endoscopic myotomy: a series of 500 patients. J Am Coll Surg 2015; 221: 256-264.
Nabi Z, Ramchandani M, Chavan R, et al. Per-oral endoscopic myotomy for achalasia cardia: outcomes in over 400 consecutive patients. Endosc Int Open 2017; 5: 331-339.
Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454.
Byth K, Cox D. On the relation between initial value and slope. Biostatistics 2005; 6: 395-403.
Vakil N, Van Zanten SV, Kahrilas P, et al; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920.
Werner YB, Hakanson B, Martinek J, et al. Endoscopic or surgical myotomy in patients with idiopathic achalasia. N Engl J Med 2019; 381: 2219-2229.
Kumbhari V, Tieu AH, Onimaru M, et al. Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study. Endosc Int Open 2015; 3: 195-201.
Rodríguez de Santiago E, Mohammed N, Manolakis A, et al. Anterior versus posterior myotomy during poem for the treatment of achalasia: systematic review and meta-analysis of randomized clinical trials. J Gastrointestin Liver Dis 2019; 28: 107-115.
Tyberg A, Seewald S, Sharaiha RZ, et al. A multicenter international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. Gastrointest Endosc 2017; 85: 1208-1211.
Liu ZQ, Li QL, Chen WF, et al. The effect of prior treatment on clinical outcomes in patients with achalasia undergoing peroral endoscopic myotomy. Endoscopy 2019; 51: 307-316.
Nabi Z, Ramchandani M, Chavan R, et al. Peroral endoscopic myotomy in treatment-naïve achalasia patients versus prior treatment failure cases. Endoscopy 2018; 50: 358-370.

Auteurs

Sunil Gupta (S)

Westmead Hospital, Sydney, NSW.
Westmead Clinical School, University of Sydney, Sydney, NSW.

Mayenaaz Sidhu (M)

Westmead Hospital, Sydney, NSW.
Westmead Clinical School, University of Sydney, Sydney, NSW.

Xuan Banh (X)

Princess Alexandra Hospital Health Service District, Brisbane, QLD.

Joseph Bradbear (J)

Princess Alexandra Hospital Health Service District, Brisbane, QLD.

Karen Byth (K)

Western Sydney Local Health District Research and Education Network, Sydney, NSW.
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW.

Luke F Hourigan (LF)

Princess Alexandra Hospital Health Service District, Brisbane, QLD.
Gallipoli Medical Research Institute, University of Queensland, Brisbane, QLD.

Spiro Raftopoulos (S)

Sir Charles Gairdner Hospital, Perth, WA.

Michael J Bourke (MJ)

Westmead Hospital, Sydney, NSW.
Westmead Clinical School, University of Sydney, Sydney, NSW.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH